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Cyclic and Macrocyclic Peptides as Chemical Tools To
Recognise Protein Surfaces and Probe Protein–Protein
Interactions
Teresa A. F. Cardote and Alessio Ciulli*[a]
Introduction
Protein–protein interactions (PPIs) control and regulate cellular
processes including enzyme catalysis, cell signalling and devel-
opment, and protein homeostasis. PPIs strongly influence the
abundance and cellular localisation of the proteins involved,
and often determine the specificity and fidelity of their func-
tion. The importance of PPIs is further underscored by the
highly organised and responsive protein networks that regu-
late most biological processes, which offer many opportunities
for therapeutic intervention. In theory, each PPI in such net-
works may play a role in physiological and pathophysiological
states, and could thus represent a prospective drug target
with potential therapeutic relevance.[1] In this context, the de-
velopment of chemical tools or probes that can help us under-
stand and dissect the mechanisms and biological roles of spe-
cific PPIs is of extreme relevance.
In spite of the vast opportunities provided by targeting PPIs,
the physicochemical nature of protein–protein interfaces
makes it a serious challenge to develop small molecules that
bind to these sites and potentially disrupt these contacts. PPIs
usually involve flat surfaces of extended area, in contrast to
the more traditional binding sites defined at the active sites of
receptors or enzymes, which tend to be more buried from sol-
vent and contain well-defined and deep pockets. Therefore,
the reliable identification and development of binding ligands
to protein surfaces, whether they be direct or allosteric modu-
lators of PPIs, remain difficult and unsolved problems. Howev-
er, much progress has been made in recent years in this direc-
tion. In particular, it is becoming increasingly clear that the de-
velopment of drug-like PPI inhibitors, and small-molecule li-
gands to protein surfaces in general, greatly benefits from the
availability of a peptidic ligand to that binding site, either from
the natural interacting partner or from synthetic sources. Some
notable successful examples of using peptides from the natural
protein partner as a starting point for drug design include
such well-characterised systems as MDM2–p53[2] and VHL–
HIF1a.[3] Such peptidic ligands can provide information about
the nature and details of the key interactions required to ach-
ieve affinity at the targeted binding site, and can furnish cru-
cial displacement tools to ensure the specificity of interactions
of the chemical series developed in the drug development
process. Peptides also offer an interesting alternative in their
own right as PPI modulators, with a number of advantages
over nonpeptidic small molecules : biocompatibility, presenting
low toxicity to the organism; chemical flexibility, which enhan-
ces the capacity to adapt to large and often flexible surfaces;
and modularity, which expands structural diversity, thereby fa-
cilitating selectivity and high potency.[4] Additionally, peptides
are able to more closely mimic the features of a protein inter-
face, and as such they constitute suitable candidates as chemi-
cal tools to target PPIs. On the other hand, the use of peptides
as drugs themselves has major drawbacks, especially in com-
parison with proteins, antibodies, or drug-like compounds;
these drawbacks include low plasma stability, cleavage by cel-
lular proteolytic enzymes, and in vivo clearance by hepatic and
renal activities.[5] Attempts to use short peptides to mimic pro-
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tein a helices important in a given PPI have had some success,
but face limitations mainly due to the sequence and context
dependence of peptide helicity, often resulting in peptides
that lack the desired helical structure in solution, which is re-
quired for productive interaction. This problem has been par-
tially addressed by the peptide-stapling approach, which was
extensively reviewed recently[6] and is not covered here. In
a complementary strategy, nonpeptide compounds have been
successfully developed to mimic the key interactions formed
by the i, i+4, and i+7 side-chains of a helices present at
PPIs.[7] However, these approaches have tended to result in
poorly soluble compounds that exhibit limited target selectivi-
ty and low cellular potency,[8] and have not been applied
across a wide range of biological sequences and PPI targets.
To circumvent these issues and to enable the use of pep-
tides as chemical tools and therapeutic leads, scientists have
been creatively modifying biologically active peptides into
molecules with more adequate structural features and physico-
chemical properties.[9] This review focuses on cyclic and macro-
cyclic peptide ligands as chemical tools to recognise protein
surfaces and for use as chemical probes of PPIs.
Head-to-tail cyclic peptides
Naturally occurring peptides often present cyclic conforma-
tions (Figure 1). In the majority of cases, ring structures are
formed by disulfide bridges between cysteine residues. Howev-
er, this is not the only possibility and cyclisation can also be
achieved through the formation of amide bonds or aryl–aryl
linkages. Examples of such cyclic structures are found from ani-
mals to lower plants.[10] Head-to-tail cyclic peptides belong to
this latter group, being the most common type, and typically
form a ring via amide bond formation between the N-terminal
amine and the C-terminal carboxylic acid. In discussing head-
to-tail cyclic peptides, a remark should be made about the
Arg-Gly-Asp (RGD)-bearing peptides[11] as one of the first exam-
ples demonstrating the benefits of cyclisation in terms of in-
creasing the stability and affinity of cyclic peptides relative to
their linear versions.[12] Through this section we present and
discuss some of the approaches taken to obtain head-to-tail
cyclic peptides and their applications in modulating PPIs.
The head-to-tail cyclisation can be reproduced synthetically
by using liquid-phase peptide synthesis, solid-phase peptide
synthesis (SPPS), or DNA-programmed chemistry,[13] and also
biosynthetically, with typical examples including phage display
approaches[14] and split-intein circular ligation of peptides and
proteins (SICLOPPS).[15] Several examples of head-to-tail cy-
clised peptides that effectively target PPIs have been described
by the Tavassoli research group. One of the examples is the
identification of cyclic peptides that interfere with the HIV Gag
protein–TSG101 host protein interaction, an important contact
involved in HIV virus outflow.[16] In this case the authors com-
bined the use of SICLOPPS libraries with a bacterial reverse
two-hybrid system (RTHS)[17] to identify cyclic peptide disrup-
tors of this PPI. Using this approach against a different target,
the same group reported the identification of cyclic hexapepti-
des that inhibit hypoxia inducible factor (HIF) heterodimerisa-
tion with high intracellular activity. Of the four cyclic peptides
retrieved from a plasmid-encoded library of 3.2Õ106 cyclic
peptides, cyclo-CLLFVY (or P1) revealed the capacity to disrupt
HIF-1 heterodimerisation by binding the PAS-B domain of HIF-
1a, without affecting HIF-2a.[18] Using the same approach as in
the previous examples, cyclic peptides were used to inhibit the
dimerisation of the C-terminal binding protein (CtBP) transcrip-
tional repressor.[19] The cyclic peptide CP61 was found to dis-
rupt CtBP homo- and heterodimerisation at 20 mm in vitro and
to inhibit the cellular functions of CtBPs at 50 mm. Human
breast cancer cells treated with the compound showed de-
creased mitotic fidelity, proliferation, and colony-forming po-
tential. The authors suggest that a di- or tripeptide motif is
crucial for the inhibitory activity of the cyclic peptide, with the
rest of the peptide acting as a backbone that presents the
active motif to its target.[19]
Another recent successful example of head-to-tail cyclic pep-
tides as PPI inhibitors was reported by Wu et al. , targeting the
Ras–effector interaction.[20] The peptide identified as the most
potent binder in vitro (IC50=0.83 mm) included unnatural
amino acids that were introduced to allow structural diversity
Figure 1. Naturally occurring cyclic peptides: Crystal and chemical structures of cyclosporin A from the fungus Tolypocladium inflatum (PDB ID: 2X7K), sun-
flower trypsin inhibitor (STF-1) from sunflower seeds (PDB ID: 1JBL), and Rhesus q defensin 1 (RTD-1) found in Rhesus macaque (PDB ID: 1HVZ).
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and resistance to proteolytic cleavage, but showed poor mem-
brane permeability. This peptide was subsequently optimised
into a higher potency Ras inhibitor (IC50=0.12 mm) that exhibit-
ed high cell permeability and induced apoptosis in cancer
cells, making it a useful lead for further development into ther-
apeutic agents.[21] This work validates the strategy of integrat-
ing target-binding and cell-penetrating motifs into a single
cyclic peptide to develop biologically active inhibitors against
other PPIs.
Side-chain-to-side-chain cyclic peptides
Side-chain-to-side-chain cyclisation is another approach that
has been extensively explored to obtain cyclic peptides via
linkage between amino acid side-chain groups. In particular,
lactam-bridged peptides have been used to introduce rigidity
and defined a-helical secondary structure in short peptides.
Some effective examples of this approach are featured. Using
macrolactam constraints between amino acid side-chains, Mills
et al.[22] reported the first a-helical peptidomimetics targeting
viral RNA. Their synthetic approach involved SPPS with orthog-
onal Pd0-labile protecting groups on the relevant lactam pre-
cursors, followed by on-resin lactam formation. The tightest
binder presented a KD value of 40 nm and, interestingly,
showed 25-fold improvement in its binding specificity toward
the target, the HIV Rev-responsive element (RRE) RNA, relative
to the corresponding linear precursor. These very encouraging
results demonstrate the feasibility of developing peptidic li-
gands with binding affinities in the nanomolar range. Using
a similar approach, i.e. , lactam bridges between amino acid
side-chains, the Fairlie research group developed a strategy for
inducing peptide helicity by rationally linking together cyclic
helical modules as short as five amino acids.[8] This helix pre-or-
ganisation resulted in significant enhancements in affinity and
specificity over unconstrained peptides, and the functional re-
sponses were similar to or greater than those of the native
proteins from which they were derived. This approach holds
potential for rational structure-based design using native pro-
tein structures and combinatorial helix libraries. Furthermore, it
successfully demonstrates the ability to downsize proteins
from different sources, including bacterial, viral, and human, to
short synthetic peptides with strategically enforced water-
stable a-helical structures.[8]
Computational approaches can aid the rational design of
cyclic peptides with biological activities. An example of this is
a study targeting the post-synaptic density protein 95 (PSD-
95), a protein that plays an important role in synaptic plasticity.
Molecular modelling of a protein–peptide complex of the third
PDZ domain (PDZ3) of PSD-95 supported the design of inhibi-
tors of this PPI. Based on in silico studies, a-, b-, and g-amino
acids were chosen as bridging elements to tether amino- and
carboxy-functionalised residue side-chains.[23] The resulting
cyclic peptides employed a bis-carboxylic acid as bridging con-
straint between two amino-containing side-chains from the
peptide backbone, and exhibited binding affinities in the
single- to double-digit micromolar range.
Different side-chain-to-side-chain cyclic peptides are those
bridged by cysteine disulfide bonds, as illustrated by the fol-
lowing two examples. The first reports cyclic peptides with
greater affinity for the CREB binding protein (CBP) bromodo-
main than their biological ligands, including lysine-acetylated
histones and tumour suppressor p53.[24] The authors used
a target-structure-guided and computer-aided rational design
approach to develop a series of disulfide-linked cyclic peptides
for testing in a functional assay. Concerned with the stability of
the disulfide bridges inside cells, the authors then modified
the most promising peptides, replacing the disulfide by a thio-
ether-like linker. This work resulted in a series of cyclic peptides
in which the best binder exhibited a KD value of 8.0 mm, repre-
senting a 24-fold improvement in affinity in comparison with
the linear lysine 382-acetylated p53 peptide.[24] The second ex-
ample concerns the development of a cyclic peptide with po-
tential use as a model for the inhibition of the recognition
mechanism of HECT-E3 ligase.[25] The HECT-containing E3 ligase
Itch mediates the degradation of several substrate proteins, in-
cluding p63, by recognizing a specific region of p63 that con-
tains a PPxY motif. In this work the authors developed a strat-
egy for the stabilisation of the conformation of an 18-mer pep-
tide derived from the recognition epitope on p63, and showed
that the cyclisation of this peptide enhanced its biological sta-
bility and binding affinity. This is a good starting point for the
development of drugs that inhibit the Itch E3 ligase complex
in vivo.
Macrocyclics and macrocycle organopeptide
hybrids
Merging the biological and synthetic approaches for attaining
macrocyclic ligands provides opportunities for ligand diversifi-
cation in drug discovery. An approach developed by Fasan and
co-workers uses macrocyclic organopeptide hybrids (MOrPHs)
incorporating non-proteogenic synthetic moieties into geneti-
cally encoded peptidic frameworks.[26] MOrPHs are based on
the reactivity of intein proteins[27] and take advantage of the
opportunity to introduce bioorthogonal functionalities into
proteins by amber stop codon suppression.[28] These modular
assemblies can be easily diversified by altering the nature of
the synthetic or biosynthetic precursors. A chemoselective
tandem reaction can be performed in the presence of two
functional groups with orthogonal reactivity to promote the
formation of the organopeptide macrocycle. Using this strat-
egy, several MOrPHs have been prepared that exhibit various
ring sizes, structures, and composition and molecular weight,
ranging from 700 to 1800 Da.[26]
Interested in probing the potential of MOrPHs for a-helix
stabilisation and mimicry, the same research group designed
MOrPH-based peptides that target HDM2/X based on a 12-mer
linear peptide isolated by phage display: PMI (Figure 2).[29] The
available crystal structure of PMI bound to HDM2 highlighted
the presence of two solvent-exposed residues as viable side-
chain attachment points for the MOrPH. The resulting mole-
cules are the first examples of side-chain-to-tail peptide cyclisa-
tion to aid a-helix stabilisation and led to the discovery of sub-
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micromolar inhibitors of the p53–HDM2/X interaction.[30] The
work also describes the influence of the nonpeptidic moiety in
the modulation of the functional, conformational, and stability
properties of a-helical MOrPHs, demonstrating the potential of
coupling this approach with a display method as a tool to
identify MOrPH compounds with tuned protein binding prop-
erties.
In a distinct strategy, using the DNA-programmed chemistry
(DPC) method[31] for directly translating DNA sequences into
small molecules, Seigal et al. developed extensive libraries of
DNA-encoded macrocycles.[32] The authors describe the con-
struction of macrocycle libraries using 20 different amino acid
building blocks for each of the derivatisable positions and five
azido-substituted amino acids in a precise position to allow co-
valent attachment to the DNA-encoding template. The screen-
ing of these libraries against the BIR2 and BIR3 domains of the
X-linked inhibitor of apoptosis protein (XIAP) led to the iden-
tification of novel macrocycles with high affinity. This example
shows that producing libraries by DPC is an efficient way to
screen for novel macrocyclic inhibitors and to generate mean-
ingful structure–activity relationships (SAR).
Finally, we report thioether macrocyclic N-methyl-peptide in-
hibitors of the E6AP E3 ubiquitin ligase identified from a ribo-
some-expressed de novo library.[33] Using translation machinery
under reprogrammed genetic code coupled with an in vitro
display technique called RaPID (random nonstandard peptides
integrated discovery), the macrocyclic N-methyl-peptides were
screened, resulting in a selection of strong anti-E6AP binders
(KD values ranging from sub-nanomolar to single-digit nano-
molar), one of which with the ability to inhibit poly-ubiquitina-
tion of substrate proteins.
Bicyclic peptides
Bicyclic peptides can be simply defined as cyclic peptides con-
taining two loops. Among possible ways to form such bicyclic
structures are side-chain-to-side-chain linkages on monocyclic
peptides as well as covalent linking units attached to three dif-
ferent points on a linear peptide. Bicyclic peptides tend to
have a more constrained structure than their monocyclic coun-
terparts. One of the most attractive features of bicyclic pep-
tides is the display of relatively flexible loops constrained to
a more rigid central scaffold, which allows closer mimicry of
antibodies in terms of their molecular recognition, binding af-
finity, and specificity properties. In addition, these structural
features have been shown to introduce improvements in bind-
ing affinities as well as resistance to intracellular degradation
and metabolic activities. Several examples have been reported
for different and successful constructions of bicyclic peptides,
some of which are discussed here.
The introduction of side-chain-to-side-chain staples in pep-
tide macrocycles can be used as a means of stabilising them.
Quartaro and colleagues[34] reported a strategy for the genera-
tion of bicyclic peptides using this approach. The starting
point was an 11-mer disulfide-bridged macrocycle named G1
that binds the Src-homology 2 (SH2) domain of growth-factor-
bound protein 2 (Grb2). G1 had been subjected to several
rounds of optimisation, allowing the authors to take advantage
of previously known SAR[35] to help design bicyclic peptide an-
alogues. The approach resulted in a bicyclic macrocycle with
a 60-fold improvement in inhibitory potency and 200-fold in-
creased selectivity relative to the original peptide after only
two rounds of iterative design.[34] To impart generality and ap-
plication of this strategy to any given cyclic peptide will, how-
ever, require systematic exploration of cross-link positions to
optimise functional properties and to identify ideal staples for
each cyclic peptide.
Substantial research has been directed in the Heinis labora-
tory toward the development and optimisation of bicyclic pep-
tides to target different proteins. In 2009 Heinis et al.[36] pre-
sented a new strategy for selecting ligands based on bicyclic
peptides attached covalently to an organic core scaffold. The
peptides contain three reactive cysteine residues, which allow
conjugation with 1,3,5-tris-(bromomethyl)benzene (TBMB),
thereby giving rise to two peptidic loops linked by a mesitylene
core. The cysteine residues were spaced apart by a variable
number of random amino acids, and the peptides were fused
to the phage gene-3-protein, permitting the screening of vast
libraries of bicyclic peptides with the convenience of phage
display. One of the first successful examples described the
screening of a library of 4.0Õ109 different chemically constrain-
ed bicyclic peptides to identify a selective and potent (Ki=
53 nm) inhibitor (UK18) of human urokinase-type plasminogen
activator (uPA).[37] The crystal structure of the peptide–protein
complex revealed that this peptide (<2 kDa) resembles fea-
tures typical of PPIs, such as a large interface of interaction
with the target and multiple hydrogen bonds and electrostatic
interactions from both peptidic loops, contributing to its bind-
ing affinity and specificity (Figure 3).[37] The same group tested
the effect of different chemical cores in the variation of the
backbone conformation adopted by the peptide loops. Studies
with three different scaffolds led to the conclusion that differ-
ent alkylating reagents impose different constraints on the
backbone conformation of bicyclic peptides.[38] This strong
structural effect was not entirely expected due to the relative
flexibility of the cysteine side-chains that react with the chemi-
cal core. The authors proposed that this dominant effect is re-
lated to the chemical moiety being the central location and
forming the branching point of the peptide. Other protein sur-
faces successfully targeted since then, using the same bicyclic
peptide approach, include the human plasma kallikrein
Figure 2. MOrPH molecule design: Crystal structure of HDM2 bound to the
peptide PMI (at left) and structural representation of the MOrPH molecule
designed based on PMI (right).
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(hPK),[39] the coagulation factor XII,[40] the epidermal growth
factor receptor Her2,[41] and more recently the Notch1 recep-
tor.[42] The characterisation of these phage-selected bicyclic
peptides revealed high proteolytic stability relative to linear or
monocyclic analogues, and most of them showed good stabili-
ty in blood plasma.[43] In addition, to prevent renal clearance,
a bicyclic peptide inhibitor of the uPA was successfully conju-
gated to albumin-binding peptides, which resulted in an ex-
tended half-life of ~24 h in mice.[44]
Lian and others developed an approach to obtain bicyclic
peptide libraries including non-proteinogenic (and certain un-
natural amino acids) and nonpeptidic building blocks, thereby
expanding their structural diversity.[45] The main difference re-
garding the previous examples relies on the fact that these li-
braries are entirely synthetic. The screening of a library con-
taining the trimesic acid as a scaffold against tumour necrosis
factor-a (TNFa) yielded 12 bicyclic peptide hits, of which six
showed dissociation constants between 1 and 8 mm. The most
active peptide exhibited high selectivity toward the target and
a binding affinity of 0.45 mm, representing the most potent
non-protein TNFa inhibitor reported until then.[45] The same
group reported the development of bicyclic peptides with cell
permeability by attaching them to cell-penetrating peptides
(CPPs),[46] which have been widely used to deliver drugs, DNA,
RNA, proteins, and nanoparticles into mammalian cells and tis-
sues. Protein tyrosine phosphatase 1B (PTP1B) was selected as
a model system, and PTP1B inhibitors were identified in
a screen of bifunctional cyclic peptides featuring the CPP motif
and a random pentapeptide sequence.[47] It is suggested that
this delivery method combining cell-penetrating and target-
binding sequences into cell-permeable inhibitors could be
generalisable and extended to other intracellular targets. Taken
together, these results encourage future development and
optimisation of bicyclic peptides into potential therapeutic
drugs.
Grafted peptides
The use of small proteins that are able to perform the same
functions as large proteins has gained popularity in recent
years, leading to the expression and even synthesis of modi-
fied miniature proteins, called mini-proteins. Disulfide-rich
mini-proteins were found to occur naturally in plants (called
cyclotides), and due to their size and stability represent an at-
tractive starting point for the development of novel PPI modu-
lators. In fact, grafted peptides are molecules that use cyclo-
tides as scaffolds for the introduction of epitopes with biologi-
cal activities.[4] Examples of effective application of grafted
peptides for targeting PPIs have been described. Ji et al. engi-
neered a cyclotide that is able to activate the p53 tumour-sup-
pressor pathway in vivo.[48] The resulting molecule was found
to be a nanomolar-affinity binder with high stability in human
serum. In a different study, the Brunsveld research group de-
veloped mini-proteins as androgen receptor co-activator
mimics through a computational design approach.[49] The au-
thors subsequently performed SAR studies of mini-proteins in
which synthetic point mutations were made in two of the
most potent inhibitors from the previous series, in order to
achieve higher potency.[50] These mutations were designed to
maintain the secondary structure of the backbone while in-
creasing the binding affinity through additional favourable in-
teractions at the receptor surface, and resulted in a tenfold
gain in potency.
Exciting work published in 2012 by Zoller et al.[51] reports the
combination of phage display and molecular grafting to gener-
ate tumour-targeting mini-proteins. A double-disulfide-stabi-
lised mini-protein called Min-23[52] was used as a molecular
scaffold in a phage display combinatorial library, leading to the
identification of new disruptors of the interaction between the
angiogenesis marker d-like ligand 4 (Dll4) and Notch1. To over-
come synthetic issues of the peptide hits, the expected bind-
ing residues of the Min-23 phage-display-evolved peptide
were transferred to the variable loop of STF-1 (sunflower tryp-
sin inhibitor), a cyclic 14-residue peptide with a single disulfide
Figure 3. Binding mode and interactions of bicyclic peptides at protein surfaces: A crystal structure of the bicyclic peptide UK18 bound to the urokinase-type
plasminogen activator (uPA) is shown at left ; the bicyclic peptide’s conformation reveals extended contacts with the protein surface. At right is the chemical
structure of UK18, highlighting the chemical scaffold TBMB.
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bridge. Several mini-proteins were synthesised and tested for
binding, and only one showed specific binding interactions
with a KD value of 22 nm. This study serves as a proof of con-
cept of applying molecular grafting to the development of
new molecular entities for therapeutic use. These mini-proteins
were active and specific in vitro and in vivo and were shown
to accumulate in tumour tissue, although further optimisation
is warranted.
Photoswitchable peptide PPI inhibitors
The ability to monitor and regulate the activity of PPI inhibitors
with spatiotemporal control opens up the possibility to control
their kinetics and site of action in cells. Photoswitchable inhibi-
tors are molecules that only adopt their active/inhibitory con-
formation when exposed to light of a certain wavelength
(Figure 4). Therefore, they offer tunable perturbations of bio-
molecular interactions, allowing regulation of timing and
period of activity of the modulators, using light as an external
stimulus with high temporal and spatial precision.[53] This strat-
egy has been applied by several groups, and a few examples
are discussed below.
To control clathrin-mediated endocytosis (CME) in living
cells, Nevola et al.[54] developed photoswitchable peptide inhib-
itors that target AP2, a complex responsible for internalising
cargo in this pathway. Disruptor molecules were designed by
starting from a crystal structure of the C-terminal peptide of
the native interaction partner, b-arrestin, bound to AP2. The
binding mode consists of an a-helical structure with four con-
served residues facing the binding pocket. The stability of the
secondary structure of peptides is strongly linked with the abil-
ity to interact with their target, and this observation led to the
hypothesis that one could reversibly regulate the peptides’ af-
finity by controlling their secondary structure. To achieve this
objective, a photoisomerisable cross-linker, 3,3’-bis(sulfonate)-
4,4’-bis(choloroacetamido)azobenzene (BSBBA), was conjugat-
ed between pairs of cysteines introduced in the peptide se-
quence, so that the stability of the helix could be reversibly al-
tered by using 380 nm or 500 nm light. The developed cell-
permeable peptides TL-1 and TL-2 were able to disrupt the
target PPI in a photocontrolled manner.[54] Using the same azo-
benzene linker (BSBBA) acting as a cyclising unit for peptides,
by attaching them to the chemical moiety from two different
points, a method to screen cyclic peptide libraries by phage
display was developed by Heinis and co-workers.[55] The au-
thors described the cyclisation of a library of the format
ACX5CG (where X are random amino acid residues) with BSBBA
and screening against streptavidin. The peptides were exposed
to UV light prior to affinity panning with the aim of isolating li-
gands that bind preferentially in the cis conformation. The best
binder identified showed a KD value of 2.2 mm, but the changes
in affinity by exposure to UV light did not enhance the affinity
drastically. In the future this limitation could be overcome by
applying different peptide library formats or different photo-
switchable moieties.[55]
The last application described here reports photoactive
phosphopeptide mimetics as potent, light-switchable inhibitors
of the protein tyrosine phosphatase PTP1B.[56] A benzoyl phos-
phonate containing amino acid, 4-phosphonocarbonyl phenyl-
alanine, was used to replace the native phosphotyrosine resi-
due. Irradiation of this benzoylphosphonate under the right
conditions and subsequent recognition by a phosphotyrosine
binding pocket led to photocross-linking of the target protein.
The peptide mimetics synthesised were validated as inhibitors
of PTP1B, and it was shown that irradiation with 365 nm light
strongly enhanced the inhibitory effects. PTP1B deactivation
was found to occur via a radical mechanism and could be re-
verted by the addition of dithiothreitol (DTT) as reducing
agent.
Summary and Outlook
The relevance of developing peptide-like molecules that target
specific protein–protein interactions has been underpinned by
approaches to obtain cyclic peptides and organopeptide hy-
brids and their respective applications. The achievements in
this area, including an increasing number of chemical strat-
egies for constraining peptide secondary structure, will no
doubt reinforce the importance of peptide binding epitopes as
lead structures.
One of the biggest challenges faced in the field remains sur-
passing the poor oral bioavailability and liabilities associated
with poor pharmacokinetics (PK), pharmacodynamics (PD), and
absorption, distribution, metabolism, excretion and toxicity
(ADMET) properties that any type of peptidic ligand inherently
suffers when used in cellular models and in vivo. Advances
have been made toward optimisation of the oral bioavailability
and membrane permeability of peptidic ligands in recent
years[57] and corroborate the enhanced properties of constrain-
ed peptides over their linear vectors. Improved in vivo lifetime
has also been achieved, for example by replacing a-amino acid
residues with homologous b-residues[58] or by coupling them
to small molecules that bind reversibly to serum proteins.[59]
Figure 4. General representation of the photoswitchable peptide approach:
The peptide is linked to an isomerisable chemical moiety, which, upon irradi-
ation with light of a certain wavelength, changes conformation and forces
the peptide to adopt a specific structure.
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Successful targeting of PPIs often requires a bilateral rela-
tionship between the protein and the ligand involved; there-
fore, efforts have also been pursued in understanding which
characteristics of a protein target might make it more suitable
for productive binding by macrocyclic ligands.[60] This knowl-
edge would definitely provide guidelines for the development
of macrocyclic ligands with enhanced structural and physico-
chemical properties and better bioavailability.
Although there is still a long road ahead, the advances re-
ported herein have increased our understanding of the re-
quirements imposed on peptidic PPI modulators as potential
therapeutics. These advancements have significantly boosted
the field, as reflected by the increasing number of publications,
building confidence that the approach is feasible and likely to
deliver major breakthroughs in terms of novel chemical tools
and potential new drugs in the near future.
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